Fas

New Research Proves the Importance of Bank Wealth Management Divisions in a Post-COVID Environment

Tuesday, September 14, 2021 - 6:30pm

The report is based on qualitative interviews with 24 bank broker-dealer executives and 4 bank executives with oversight of the branch channel.

Key Points: 
  • The report is based on qualitative interviews with 24 bank broker-dealer executives and 4 bank executives with oversight of the branch channel.
  • "Over the last 18 months we have experienced a dramatic shift in how we interact with clients and prospects.
  • Bank BDs play a critical role in helping banks create differentiated service for affluent clients, in part through branch-based FAs.
  • To learn more about becoming a member of BISA and obtaining this report, contact bisa@BISAnet.org .

Timber Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Friday, September 10, 2021 - 10:58pm

BASKING RIDGE, NJ, Sept. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire Timber Pharmaceuticals, Inc. ("Timber" or the Company) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

Key Points: 
  • BASKING RIDGE, NJ, Sept. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire Timber Pharmaceuticals, Inc. ("Timber" or the Company) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference.
  • An on-demand corporate presentation will be accessible to conference attendees starting on Monday, September 13th, 2021 at 7:00 am ET and available for the duration of the conference.
  • For more information regarding the conference or to schedule a one-on-one meeting with management, please visit the H.C. Wainwright conference website https://hcwevents.com/annualconference/ .
  • Timber Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases.

Timber Pharmaceuticals Announces Last Patient Last Visit in Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis

Tuesday, August 24, 2021 - 1:00pm

Basking Ridge, N.J., Aug. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the last patient completed their last visit in the Phase 2b CONTROL study evaluating TMB-001, a topical isotretinoin formulated using Timber’s patented IPEG™ delivery system, in patients with moderate to severe subtypes of congenital ichthyosis (CI). The IPEG delivery system was designed to maximize isotretinoin delivery into pathologic skin layers, while minimizing systemic absorption. 

Key Points: 
  • With this important milestone we are now one step closer to reporting topline data from the study and moving forward with Phase 3 trial planning.
  • CI is a group of rare, genetic keratinization disorders that lead to dry, thickened, and scaling skin.
  • The randomized, parallel, double-blind, vehicle-controlled Phase 2b CONTROL study randomized 34 patients aged nine years old and older.
  • Timber Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases.

Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2021 Financial Results

Tuesday, August 10, 2021 - 1:00pm

BASKING RIDGE, NJ, Aug. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire --Timber Pharmaceuticals, Inc. ("Timber" or the Company) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the second quarter ended June 30, 2021.

Key Points: 
  • BASKING RIDGE, NJ, Aug. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire --Timber Pharmaceuticals, Inc. ("Timber" or the Company) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the second quarter ended June 30, 2021.
  • John Koconis, Chairman and Chief Executive Officer of Timber, commented, In the second quarter Timbers core programs for rare and orphan dermatologic diseases all continued to progress.
  • Timber expects to announce top line results from the Phase 2b CONTROL study in the fourth quarter of 2021 and is planning for an end-of-Phase 2 meeting with the FDA by the end of the year.
  • Timber ended the second quarter with $6.1 million in cash and common shares outstanding of 36.7 million at June 30, 2021.

Magnit announces approval by the Federal Antimonopoly Service of the DIXY business acquisition

Friday, July 16, 2021 - 1:51am

Krasnodar, Russia (July 15, 2021): Magnit PJSC (MOEX and LSE: MGNT; the Company), one of Russia's leading retailers, announces it has received an approval from the Federal Antimonopoly Service ("FAS") in connection with the acquisition of 100% shares of the DIXY Holding Limited (Cyprus) by JSC "Tander", main operating vehicle of Magnit.

Key Points: 
  • Krasnodar, Russia (July 15, 2021): Magnit PJSC (MOEX and LSE: MGNT; the Company), one of Russia's leading retailers, announces it has received an approval from the Federal Antimonopoly Service ("FAS") in connection with the acquisition of 100% shares of the DIXY Holding Limited (Cyprus) by JSC "Tander", main operating vehicle of Magnit.
  • According to the agreement Magnit acquires a holding entity for a group of companies that operate convenience stores under the DIXY brand and superstores under the Megamart brand in three federal districts.
  • As part of the transaction Magnit will also acquire distribution centers and a truck fleet.
  • No further approvals after today's clearance by Federal Antimonopoly Service are required.

HeadHunter Group PLC Announces the Decision of Federal Antimonopoly Service

Monday, January 27, 2020 - 1:00pm

MOSCOW, Jan. 27, 2020 (GLOBE NEWSWIRE) -- HeadHunter Group PLC (Nasdaq: HHR) is pleased to announce that the Federal Antimonopoly Service of Russia (FAS or the Antitrust Agency) has issued a final decision on the case initiated in April 2019 pursuant to a complaint by Stafori LLC (Stafori), as disclosed earlier.

Key Points: 
  • MOSCOW, Jan. 27, 2020 (GLOBE NEWSWIRE) -- HeadHunter Group PLC (Nasdaq: HHR) is pleased to announce that the Federal Antimonopoly Service of Russia (FAS or the Antitrust Agency) has issued a final decision on the case initiated in April 2019 pursuant to a complaint by Stafori LLC (Stafori), as disclosed earlier.
  • As used herein, references to we, our, us or the Company or similar terms shall mean HeadHunter Group PLC and any and all its subsidiaries.
  • Importantly, the Antitrust Agency has concluded that our actions do not limit overall competition in Russias online recruitment market.
  • We also have the right to appeal the FAS decision in court, and we will analyze the merits of an appeal in due course.